MedTrace Logo

Study of ESG406 in Adults With Solid Tumors

NCT06979674 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 556

Last updated 2025-09-12

No results posted yet for this study

Summary

This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration regimens of ESG406. The study includes the dose escalation study in Phase Ia and the cohort expansion study in Phase Ib.

Conditions

  • Locally Advanced/Metastatic Solid Tumors

Interventions

DRUG

ESG406

Administered via intravenous (IV) infusion.

Sponsors & Collaborators

  • Shanghai Escugen Biotechnology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Fuming Qiu, PhD · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-04
Primary Completion
2028-04-30
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06979674 on ClinicalTrials.gov